Triplet therapy with afatinib, cetuximab, and bevacizumab induces deep remission in lung cancer cells harboring EGFR T790M in vivo

Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) have changed the treatment strategy for EGFR‐mutant lung cancers; however, resistance usually occurs due to a secondary mutation, T790M, in EGFR. Combination therapy using afatinib and cetuximab has had good results in lung tu...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
הוצא לאור ב:Mol Oncol
Main Authors: Kudo, Kenichiro, Ohashi, Kadoaki, Makimoto, Go, Higo, Hisao, Kato, Yuka, Kayatani, Hiroe, Kurata, Yasuko, Takami, Yoichiro, Minami, Daisuke, Ninomiya, Takashi, Kubo, Toshio, Ichihara, Eiki, Sato, Akiko, Hotta, Katsuyuki, Yoshino, Tadashi, Tanimoto, Mitsune, Kiura, Katsuyuki
פורמט: Artigo
שפה:Inglês
יצא לאור: John Wiley and Sons Inc. 2017
נושאים:
Research Articles
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC5467494/
https://ncbi.nlm.nih.gov/pubmed/28388009
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/1878-0261.12063
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים